Literature DB >> 20048756

Glucose tolerance and physical activity level in people with spinal cord injury.

J Raymond1, A R Harmer, J Temesi, C van Kemenade.   

Abstract

STUDY
DESIGN: Cross-sectional, observational study.
OBJECTIVES: To evaluate the associations of physical activity and neurological lesion level with glucose tolerance in people with spinal cord injury (SCI).
SETTING: New South Wales, Australia.
METHODS: Twenty-five people (5 women, 20 men) with SCI (>6 months post-injury) aged between 18 and 65 years were recruited. Exclusion criteria included known coronary heart disease, stroke or diabetes. Participants underwent an oral glucose tolerance test. Fasting and 2-h plasma glucose concentrations were classified according to the World Health Organization categories of glycemia. Participants also completed the Physical Activity Scale for Individuals with Physical Disabilities and mean MET-hours day(-1) was calculated. Associations with the 2-h plasma glucose concentration were calculated through multiple and stepwise regressions.
RESULTS: Participants presented with complete or incomplete tetraplegia (n=11 TETRA) or complete or incomplete paraplegia (n=14 PARA) with neurological lesion levels ranging from C3/4 to T12. Mean 2-h plasma glucose was 7.13+/-2.32 mmol l(-1). Nine participants had disordered glycemia (n=6 TETRA; n=3 PARA) and the remaining participants had normal glucose tolerance. Those participants with normal glucose tolerance participated in more moderate-vigorous and strength exercise and undertook more non-exercise-related mobility than those with disordered glycemia. Physical activity and age, but not lesion level were independent determinants of 2-h plasma glucose concentration (r=0.683, P=0.001), explaining 47% of the variance.
CONCLUSION: Physical activity level is independently associated with glucose tolerance in people with SCI. Non-exercise activity may also be important for maintaining normal glycemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048756     DOI: 10.1038/sc.2009.180

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  8 in total

1.  Contributors to Metabolic Disease Risk Following Spinal Cord Injury.

Authors:  Daniel L Smith; Ceren Yarar-Fisher
Journal:  Curr Phys Med Rehabil Rep       Date:  2016-07-06

2.  Benefits of an exercise wellness program after spinal cord injury.

Authors:  Deborah A Crane; Jeanne M Hoffman; Maria R Reyes
Journal:  J Spinal Cord Med       Date:  2015-06-25       Impact factor: 1.985

3.  H-FABP, cardiovascular risk factors, and functional status in asymptomatic spinal cord injury patients.

Authors:  A Akbal; A Kurtaran; B Selçuk; M Akyüz
Journal:  Herz       Date:  2013-03-14       Impact factor: 1.443

Review 4.  Neurogenic Obesity-Induced Insulin Resistance and Type 2 Diabetes Mellitus in Chronic Spinal Cord Injury.

Authors:  Phillip S Gordon; Gary J Farkas; David R Gater
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

5.  Evaluation of the Cardiometabolic Disorders after Spinal Cord Injury in Mice.

Authors:  Adel B Ghnenis; Calvin Jones; Arthur Sefiani; Ashley J Douthitt; Andrea J Reyna; Joseph M Rutkowski; Cédric G Geoffroy
Journal:  Biology (Basel)       Date:  2022-03-24

Review 6.  The neurological level of spinal cord injury and cardiovascular risk factors: a systematic review and meta-analysis.

Authors:  Gion Fränkl; Oche Adam Itodo; Peter Francis Raguindin; Alessandro Bertolo; Ramona Maria Zeh; Simona Capossela; Beatrice Minder; Jivko Stoyanov; Gerold Stucki; Oscar H Franco; Taulant Muka; Marija Glisic
Journal:  Spinal Cord       Date:  2021-08-20       Impact factor: 2.772

7.  Sclerostin Concentration and Bone Biomarker Trends in Patients with Spinal Cord Injury: A Prospective Study.

Authors:  Jong Ho Lee; Jang Hyuk Cho; Dong Gyu Lee
Journal:  Healthcare (Basel)       Date:  2022-05-25

8.  Cardiovascular disease risk marker responses to breaking up prolonged sedentary time in individuals with paraplegia: the Spinal Cord Injury Move More (SCIMM) randomised crossover laboratory trial protocol.

Authors:  Thomas M Withers; Louise Croft; Victoria L Goosey-Tolfrey; David W Dunstan; Christof A Leicht; Daniel P Bailey
Journal:  BMJ Open       Date:  2018-06-22       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.